SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells

Journal of Pathology

Volumn 217, Issue 3, 2009, Pages 389-397

  Zhi, H ^a   Yang, X J ^b   Kuhnmuench, J ^a   Berg, T ^a   Thill, R ^a   Yang, H ^a   See, W A ^a   Becker, C G ^a   Williams, C L ^a   Li, R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer; COX 2; Prostate; SmgGDS; Tumourigenesis

Indexed keywords

ANDROGEN RECEPTOR; CYCLOOXYGENASE 2; GUANINE NUCLEOTIDE EXCHANGE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SMGGDS; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; RAP1GDS1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; CARCINOMA; CELL MOTION; CHEMISTRY; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; TISSUE MICROARRAY; TUMOR CELL LINE; UPREGULATION;

CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NF-KAPPA B; PROSTATE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 60549096862     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2456     Document Type: Article

References (54)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nature Rev Cancer 2007;7:256-269.
3. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol 2002;10:153-169.
4. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-1181.
5. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005;11:3250-3256.
6. Collado B, Carmena MJ, Clemente C, Prieto JC, Bajo AM. Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides 2007;28:1896-1901.
7. Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004;58:121-129.
8. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007;67:3310-3319.
9. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 2001;61:2720- 2726.
10. Chang MS, Chen BC, Yu MT, Sheu JR, Chen TF, Lin CH. Phorbol 12-myristate 13-acetate upregulates cyclooxygenase-2 expression in human pulmonary epithelial cells via Ras, Raf-1, ERK, and NF-kappaB, but not p38 MAPK, pathways. Cell Signal 2005;17:299-310.
11. Lee KW, Kim MS, Kang NJ, Kim DH, Surh YJ, Lee HJ, et al. H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells. Int J Cancer 2006;119:1767-1775.
12. Montaner S, Perona R, Saniger L, Lacal JC. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem 1998;273:12779-12785.
13. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997;11:463-475.
14. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: integrating signals from front to back. Science 2003;302:1704-1709.
15. Schmitz AA, Govek EE, Bottner B, Van Aelst L. Rho GTPases: signaling, migration, and invasion. Exp Cell Res 2000;261:1-12.
16. Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 2006;119:1858-1862.
17. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH. Infrequent RAS oncogene mutations in human prostate cancer. Prostate 1992;20:327-338.
18. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor recep tor correlates with disease relapse and progression to androgen independence in human prostate cancer. Clin Cancer Res 2002;8:3438-3444.
19. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-1989.
20. Voeller HJ, Wilding G, Gelmann EP. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carci noma cells. Mol Endocrinol 1991;5:209-216.
21. Bektic J, Pfeil K, Berger AP, Ramoner R, Pelzer A, Schafer G, et al. Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate 2005;64:332-340.
22. Ghosh PM, Bedolla R, Mikhailova M, Kreisberg JI. RhoA- dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta. Cancer Res 2002;62:2630-2636.
23. Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA, et al. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 1999;18:4120-4130.
24. Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF. Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res 2003;63:1359-1364.
25. Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES, et al. Deregulation of the Rho GTPase, Racl, suppresses cyclin-dependent kinase inhibitor p21(CIPl) levels in androgen-independent human prostate cancer cells. Oncogene 2004;23:5513-5522.
26. Yao H, Dashner EJ, van Golen CM, van Golen KL. RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 2006;25:2285-2296.
27. Melisi D, Troiani T, Damiano V, Tortora G, Ciardiello F. Ther apeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr Relat Cancer 2004;11:51-68.
28. Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, et al. Farnesyl: protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate Cancer Prostatic Dis 2001;4:33-43.
29. Shi Y, Wu J, Mick R, Cerniglia GJ, Cohen-Jonathan E, Rhim JS, et al. Farnesyltransferase inhibitor effects on prostate tumor microenvironment and radiation survival. Prostate 2005;62:69-82.
30. Lanning CC, Ruiz-Velasco R, Williams CL. Novel mechanism of the co-regulation of nuclear transport of SmgGDS and Racl. J Biol Chem 2003;278:12495-12506.
31. Williams CL. The polybasic region of Ras and Rho family small GTPases: a regulator of protein interactions and membrane association and a site of nuclear localization signal sequences. Cell Signal 2003;15:1071-1080.
32. Chuang TH, Xu X, Quilliam LA, Bokoch GM. SmgGDS stabi lizes nucleotide-bound and -free forms of the Racl GTP-binding protein and stimulates GTP/GDP exchange through a substituted enzyme mechanism. Biochem J 1994;303:761-767.
33. Hutchinson JP, Eccleston JF. Mechanism of nucleotide release from Rho by the GDP dissociation stimulator protein. Biochemistry 2000;39:11348-11359.
34. Mizuno T, Kaibuchi K, Yamamoto T, Kawamura M, Sakoda T, Fujioka H, et al. A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21. Proc Natl Acad Sci USA 1991;88:6442-6446.
35. Yaku H, Sasaki T, Takai Y. The Dbl oncogene product as a GDP/GTP exchange protein for the Rho family: its properties in comparison with those of Smg GDS. Biochem Biophys Res Commun 1994;198:811-817.
36. Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R, Williams CL. SmgGDS regulates cell proliferation, migration, and NF-kappaB transcriptional activity in non-small cell lung carcinoma. J Biol Chem 2008;283:963-976.
37. Denkert C, Thoma A, Niesporek S, Weichert W, Koch I, Noske A, et al. Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia - association with increased expression of Polo-like kinase-1. Prostate 2007;67:361-369.
38. Remmele W, Stegner HE. [Recommendation for uniform defini tion of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987;8:138-140.
39. Varker KA, Williams CL. Involvement of the muscarinic acetylcholine receptor in inhibition of cell migration. Biochem Pharmacol 2002;63:597-605.
40. Bolick DT, Orr AW, Whetzel A, Srinivasan S, Hatley ME, Schwartz MA, et al. 12/15-lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor kappa B. Arterioscler Thromb Vasc Biol 2005;25:2301-2307.
41. Frost JA, Swantek JL, Stippec S, Yin MJ, Gaynor R, Cobb MH. Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. J Biol Chem 2000;275:19693-19699.
42. Wei CY, Huang KC, Chou YH, Hsieh PF, Lin KH, Lin WW. The role of Rho-associated kinase in differential regulation by statins of interleukin-lbeta- and lipopolysaccharide-mediated nuclear factor kappaB activation and inducible nitric-oxide synthase gene expression in vascular smooth muscle cells. Mol Pharmacol 2006;69:960-967.
43. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682-687.
44. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-430.
45. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, et al. Racl in human breast cancer: overexpression, muta tion analysis, and characterization of a new isoform, Raclb. Onco gene 2000;19:3013- 3020.
46. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, et al. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998;77:147-152.
47. Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996;78:330-336.
48. Brawer MK. Prostatic intraepithelial neoplasia: a premalignant lesion. Hum Pathol 1992;23:242-248.
49. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996;87:13-20.
50. Dassesse T, de Levai X, de Levai L, Pirotte B, Castronovo V, Waltregny D. Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. Eur Urol 2006;50:1021-1031; discussion 1031.
51. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001;58:127-131.
52. Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, et al. Cyclooxygenase-2 (COX-2) expression is an inde pendent predictor of prostate cancer recurrence. Int J Cancer 2006;119:1082-1087.
53. Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, et al. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 2001;3:287-303.
54. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, et al. Cyclooxygenase-2 is up-regulated in proliferative inflamma tory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617- 8623.